Aspartame : should individuals with Type II diabetes be taking it?

dc.contributor.authorChoudhary, Arbind Kumar
dc.date.accessioned2018-11-02T09:29:39Z
dc.date.issued2018
dc.description.abstractBACKGROUND : Individuals with Type II Diabetes (T2D) have to manage blood glucose levels to sustain health and longevity. Artificial sweeteners (including aspartame) are suggested sugar alternatives for these individuals. The safety of aspartame in particular, has long been the centre of debate. Although it is such a controversial product, many clinicians recommend its use to T2D patients, during a controlled diet and as part of an intervention strategy. Aspartame is 200 times sweeter than sugar and has a negligible effect on blood glucose levels, and it is suggested for use so that T2D can control carbohydrate intake and blood glucose levels. However, research suggests that aspartame intake may lead to an increased risk of weight gain rather than weight loss, and cause impaired blood glucose tolerance in T2D. OBJECTIVE : This review consolidates knowledge gained from studies that link aspartame consumption to the various mechanisms associated with T2D. METHOD : We review literature that provides evidence that raise concerns that aspartame may exacerbate T2D and add to the global burden of disease. RESULTS : Aspartame may act as a chemical stressor by increasing cortisol levels, and may induce systemic oxidative stress by producing excess free radicals, and it may also alter gut microbial activity and interfere with the N-methyl D-aspartate (NMDA) receptor, resulting in insulin deficiency or resistance. CONCLUSION : Aspartame and its metabolites are safe for T2D is still debatable due to a lack of consistent data. More research is required that provides evidence and raise concerns that aspartame may exacerbate prevalence of pathological physiology in the already stressed physiology of T2D.en_ZA
dc.description.departmentPhysiologyen_ZA
dc.description.embargo2019-07-01
dc.description.librarianhj2018en_ZA
dc.description.sponsorshipThe University of Pretoria Post-Doctoral Fellowshipen_ZA
dc.description.urihttps://benthamscience.com/journals/current-diabetes-reviewsen_ZA
dc.identifier.citationChoudhary, A.K. Aspartame : should individuals with Type II diabetes be taking it?' Current Diabetes Reviews. 2018;14(4):350-362. doi : 10.2174/1573399813666170601093336.en_ZA
dc.identifier.issn1573-3998 (print)
dc.identifier.issn1875-6417 (online)
dc.identifier.other10.2174/1573399813666170601093336
dc.identifier.urihttp://hdl.handle.net/2263/67138
dc.language.isoenen_ZA
dc.publisherBentham Scienceen_ZA
dc.rights© 2018 Bentham Science Publishersen_ZA
dc.subjectType II diabetes (T2D)en_ZA
dc.subjectAspartameen_ZA
dc.subjectGlucoseen_ZA
dc.subjectInsulinen_ZA
dc.subjectWeight gainen_ZA
dc.subjectWeight lossen_ZA
dc.subjectN-methyl D-aspartate (NMDA)en_ZA
dc.titleAspartame : should individuals with Type II diabetes be taking it?en_ZA
dc.typePostprint Articleen_ZA

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Choudhary_Aspartame_2018.pdf
Size:
665.51 KB
Format:
Adobe Portable Document Format
Description:
Postprint Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: